RE:RE:antiviral ...Jefnan1 wrote: Your insights are always interesting. The problem is that when they burn the cash they received before the liver problem they are done since they won't get another penny and right now they have nothing to sell. If they did don't you think that there would be some shares traded. Not just people on these sites trying to make $500
---------------------
Cash burn is an important concern and it must be managed well.
But we are drug development and now more than ever, you want to spend to grow the funnel.
Running P2 an growing the funnel - that's the purpose for the cash.
Seems to be well under control.
$20MM is now in short term securities so they are telling us they don't need it all right now.
Don't forget the three groups of warrants that could still net quite a chunck of money - depending on where the share price goes.
It's only a matter of time before Phase 2 brings investors back to the game (be it in 2022 or 2023) but I care very little about other shareholders. I care about myself the price I'm paying.
The price will move when the price moves - nothing I can do about it. Also, I think there's a lot of information that hasn't been shared yet and we've covered those areas over the past few week.
It won't be long before ATE gets attention but it's the Big Pharma attention that matters.
Frst related to 346 Acute and 352 Specialty Acute ... then regarding all the developments on the chronic side.
-------------------
As long as the company keeps focusing on developing their science and pushing OTENA (Acute) to success - I really don't care when the buyers arrive. Build it and they will come.
I see a much stronger company with better patents and deeper science. That's what matters to Big Pharma ... and to me.
I still think OTENA is going to command a biggert market than Chronic's $30B ... based on my numbers and where I think we're going. Will see what actually happens.